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PAtherosclerosis
lasma Triglycerides and Type III
yperlipidemia Are Independently Associated
ith Premature Familial Coronary Artery Disease
aul N. Hopkins, MD, MSPH,* Lily L. Wu, PHD,*† Steven C. Hunt, PHD,* Eliot A. Brinton, MD*
alt Lake City, Utah
OBJECTIVES This study was designed to explore contributions of plasma total triglycerides (TGs) and type
III hyperlipidemia to the risk of premature familial coronary artery disease (CAD).
BACKGROUND Although plasma TGs are recognized as a risk factor for CAD, the independence of this
association from related risk factors remains controversial. Also, the degree of CAD risk
conferred by excess remnants of TG-rich lipoproteins in type III hyperlipidemia remains
unclear.
METHODS We analyzed lipids by ultracentrifugation in a series of 653 cases with premature familial
CAD (myocardial infarction or revascularization by age 55 years in men or age 65 years in
women, with similar onset in at least one other first-degree relative) and in 1,029 control
subjects. The relationship of CAD risk to various strata of plasma TGs, high-density
lipoprotein (HDL) cholesterol, and type III hyperlipidemia, and interactions among these
variables were examined by multiple logistic regression, adjusting for other CAD risk factors.
RESULTS The odds ratio for CAD with elevated plasma TG rose progressively to 11.4 in those with
TGs 500 to 799 mg/dl (95% confidence interval 3.4 to 38.0, p  0.0001) compared with
100 mg/dl, even after correction for HDL cholesterol, other elements of the metabolic
syndrome, and other CAD risk factors. Risk of CAD associated with type III hyperlipidemia
(found in 3.4% of cases) was also markedly increased independent of other risk factors (odds
ratios of 5 to 10 depending on the model, all with p  0.002).
CONCLUSIONS The association between the plasma TG level and premature familial CAD is strong, graded, and
independent. Risk of CAD is also strikingly elevated with type III hyperlipidemia. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.062Cardiol 2005;45:1003–12) © 2005 by the American College of Cardiology Foundation
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slevated plasma triglyceride (TG) concentration is becom-
ng increasingly established as an independent risk factor for
remature coronary artery disease (CAD) (1–3). The excess
isk is particularly apparent in women (4–7) and in Euro-
ean studies (8–10). The high prevalence of familial TG
levations among premature CAD patients further illus-
rates the importance of hypertriglyceridemia as a CAD risk
actor (11,12). Despite this consensus, uncertainty persists
egarding the strength and independence of plasma TGs as
CAD risk factor.
Several lines of evidence suggest that the association of
lasma TGs with CAD is complex. In the Prospective
ardiovascular Munster (PROCAM) study, CAD risk
ncreased proportionately with TGs up to 800 mg/dl but
egan to diminish in persons with levels above 800 mg/dl
10). In addition, the risk associated with TGs 200 mg/dl
as dependent on concomitant low high-density lipopro-
ein (HDL)-cholesterol or elevated low-density lipoprotein
LDL)-cholesterol/HDL ratio in both PROCAM (13) and
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yriad Genetics.m
Manuscript received September 1, 2004; revised manuscript received November 22,
004, accepted November 29, 2004.n the Helsinki Heart Study (14). Chylomicronemia may
onfer low CAD risk despite very high TGs (15,16). In
ontrast, type III hyperlipidemia, which results from im-
aired removal of TG-rich lipoprotein remnants, may
ssociate with extreme CAD risk despite relatively modest
G elevations (17,18). Surprisingly, however, published
opulation-based estimates of CAD risk associated with
ype III hyperlipidemia are entirely lacking. Also, the
oderate elevations in TGs seen with metabolic syndrome
eem to be associated with moderate CAD risk (19–21).
Uncertainties regarding the independence and strength of
lasma TGs as a CAD risk factor in published studies are
ikely due both to lack of attention to the nature of TG
levations and small study size resulting in inadequate
tatistical power. We studied a large series of patients with
remature familial CAD and population-based controls.
e calculated CAD risk across the spectrum of plasma TG
evels and tested for interactions with other elements of the
etabolic syndrome. Also, for the first time we report a
opulation-based estimate of CAD risk associated with type
II hyperlipidemia determined by measurement of plasma
ipids by ultracentrifugation in all cases and controls.
ETHODS
tudy participants. Premature, familial CAD cases con-
isted of 499 men and 154 women who had survived a
yocardial infarction, percutaneous transluminal angio-
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ears for men or age 65 years for women. To minimize
rtifactual effects of the acute coronary syndrome on lipid
evels, patients were seen at least six months after their acute
vent. Each of the CAD cases was from a family in which
t least one additional first-degree relative (parent, sibling,
r child) had early CAD by this definition. The CAD cases
ame from 531 families with the following distribution of
creened relatives: 1 family had 6 affected relatives, 1 family
ad 5, 1 family had 4, 7 families had 3, 96 had 2, and the
emaining 425 families had only 1 affected relative screened.
hese cases were ascertained from two sources: 78% were
rom discharge records of Intermountain Health Care
which had between 50% and 62% of the health care market
hare in the state of Utah during the years of recruitment)
22); the remainder were ascertained through the Family
ealth Tree program (defined in later text). Recruitment of
ur CAD cases occurred throughout the 1990s, with the
ajority recruited in the middle of the decade. Initial
anifestations of CAD in cases were myocardial infarction
n 74.7%, CABG in 13.8%, and percutaneous transluminal
ngioplasty in 11.5%.
Controls included 488 men and 541 women consisting of
wo groups. The first group (527 controls) consisted of a
andom sampling of family members participating in our
amily Health Tree Program (23,24). Briefly, high school
tudents in health classes throughout Utah collected health
nformation on family members with the help of their
arents. The data were computerized and feedback provided
o students and their families regarding familial disease
endencies. Prior samples identified from Family Health
rees have been studied and found to be representative of
he Utah population (25). Upon close examination, these
ontrols tended to live in suburban areas. The second group
502 controls) was spouse pairs participating in a study of
sychological factors related to CAD. This group was
ecruited by advertising in newspapers, at conventions, and
rom the University of Utah community. As acute hemo-
ynamic responses to various stressors were tested as part of
hat study, persons taking certain vasoactive drugs (beta-
lockers, calcium channel blockers, and other anti-anginal
edication) were excluded. These controls tended to live in
rban Salt Lake City. Control subjects could not have
linically diagnosed CAD themselves, but no effort was
ade to exclude controls based on family history of CAD.
Abbreviations and Acronyms
BMI  body mass index
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CI  confidence interval
HDL  high-density lipoprotein
LDL  low-density lipoprotein
TG  triglycerideComparability of the two groups of controls was exam- cned. The age, gender, and measured blood pressure distri-
ution of the two control groups were nearly identical. The
ealth Family Tree group had significantly higher body
ass index (BMI) (28.6  5.5 kg/m2 vs. 27.2  4.6 kg/m2,
 0.0001), plasma TG (173  87 mg/dl vs. 135  104
g/dl, p  0.0001), and glucose levels (92.7  21.7 mg/dl
s. 89.8  15.5 mg/dl, p  0.015) and lower HDL-
holesterol (47.5  13.2 mg/dl vs. 53.0  16.1 mg/dl, p 
.0001) and LDL-cholesterol (103  28 mg/dl vs. 109 
8 mg/dl, p  0.0003). Prevalence of having ever smoked
aily for a year or more (18.8% vs. 26.1%, p  0.0050) and
urrent alcohol use (8.9% vs. 25.1%, p  0.0001) were
reater among the second group. A separate group of 498
tah subjects recruited randomly from Health Family Tree
amilies for a different study (the Family Heart Study; not
sed as control subjects in this study because lipids were not
easured by ultracentrifugation) (25) was also examined for
omparability with the two control groups. This comparison
roup was found to have intermediate levels of BMI (28.2
.6 kg/m2) whereas HDL-cholesterol (44.2  13.5 mg/dl)
as more similar to the other Health Family Tree cohort
nd plasma TG levels (139 78.4 mg/dl) were more similar
o the control group from the psychology study. When
ompared with other general population groups from other
ites in the Family Heart Study, the psychology study group
as intermediate between these and the Utah Tree groups
or the defined variables. Risk calculations were performed
sing each control group separately. In all instances, odds
atio estimates and trends were very similar and, in most
ategories, the odds ratio using one control group was
ncluded in the 95% confidence interval for the odds ratio
sing the other control group. Odds ratio estimates for type
II hyperlipidemia, in particular, were similar using either
ontrol group. In a few HDL-TG subcategories (particu-
arly those with TGs 300 mg/dl), estimates of odds ratios
ere unstable (fewer than five control subjects) when the
ontrol groups were considered separately. Odds ratio esti-
ates for LDL-cholesterol and non-lipid risk factors were
lso generally comparable. The two control groups were
herefore combined for all further analyses. This study was
pproved by the Institutional Review Board of the Univer-
ity of Utah Medical Center. All subjects signed informed
onsent before participating.
A participant was considered to have hypertension if
aking antihypertensive medication for a prior physician
iagnosis of hypertension, or if at screening the mean of two
itting blood pressures taken with a Critikon Dynamap
utomated blood pressure machine was 140 mm Hg
ystolic or 90 mm Hg diastolic. Diabetes was considered
resent if a prior physician diagnosis had been made or if
he fasting serum glucose upon screening was 126 mg/dl.
igarette smoking was dichotomized into “ever” or “never,”
ith ever smoking defined as having smoked daily for one
ear or more. Many patients had quit after onset of their
AD, hence the designation as ever smoking rather thanurrent and former.
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April 5, 2005:1003–12 Plasma Triglycerides, Type III Hyperlipidemia, and CAD Riskaboratory methods. Blood samples were collected in the
orning after 12 h to 16 h of fasting and prepared according
o guidelines of the Lipid Research Clinic’s program Man-
al of Laboratory Operations (26). Lipid and lipoprotein
oncentrations were measured by a microscale ultracentrif-
gation procedure developed in our laboratory (27). We
easured HDL-cholesterol by a magnetic bead precipita-
ion using dextran sulfate/MgCl2 (28). Cholesterol and
Gs in total plasma and subfractions were measured with a
oche FARA II (Roche Diagnostics, Indianapolis, Indiana)
utomated analyzer. The TG-rich lipoproteins were sepa-
ated from LDL and HDL by use of a Beckman TL100
ltracentrifuge and tube splicing. The value for very low-
ensity lipoprotein (VLDL) cholesterol was taken as the
easured cholesterol in the top fraction (density 1.006).
his value was compared to the total cholesterol minus the
holesterol in the bottom fraction (density 1.006) con-
aining LDLHDL and verified to yield virtually identical
esults. Measured LDL cholesterol was taken as the cho-
esterol measured in this bottom fraction minus HDL-
holesterol. Type III hyperlipidemia was defined as present
f the ratio of VLDL/plasma TGs was 0.30 and plasma
Gs were 150 mg/dl (17). Our laboratory participates in
he Centers for Disease Control Standardization Program
nd consistently achieves excellent agreement with Centers
or Disease Control standards (coefficients of variation in
he range of 0.5% to 3.3% for total cholesterol, TG, and
DL-cholesterol, with 3% difference in means).
tatistical analysis. The SAS Statistical Software Package
Table 1. Clinical Characteristics
Variable
CA
(n
Mean
Age (yrs) 54.9
Male (%) 76.4
BMI (kg/m2) 28.6
Hypertension (%) 58.3
Diabetes (%) 19.3
Ever smoked (%) 46.2
Alcohol use (% 1  drink/week) 11.9
Taking lipid-lowering medication (%) 27.6
Systolic BP (mm Hg) 136
Diastolic BP (mm Hg) 80.4
Glucose (mg/dl) 100.9
Albumin (mg/dl) 4.18
Bilirubin (mg/dl) 0.587
Creatinine (mg/dl) 1.064
Uric acid (mg/dl) 6.26
Total cholesterol (mg/dl) 218
Triglycerides (mg/dl) 206
HDL-cholesterol (mg/dl) 40.6
LDL-cholesterol, measured (mg/dl) 136
VLDL-cholesterol, measured (mg/dl) 40.4
Type III hyperlipidemia (%) 3.4
Cases with premature CAD are compared with population c
t test.
BMI  body mass index; BP  blood pressure; CAD 
low-density lipoprotein; VLDL  very low-density lipoprotversion 8.2) was used for data analysis (SAS Institute, Inc. Hary, North Carolina). Statistical analyses on TGs were
one after logarithmic transformation. Statistical tests in-
luded Student t test, chi-square, Pearson’s correlation, and
tepwise multiple logistic regression using SAS PROC
OGISTIC. Because some cases came from the same
amily, effects of subject relatedness were tested using
ROC GENMOD in SAS. As results were nearly identical
ith the two methods, p values obtained with PROC
OGISTIC are reported.
ESULTS
linical characteristics of premature familial CAD cases are
ompared with control subjects in Table 1. Highly signifi-
ant differences by univariate analysis were apparent for
tandard CAD risk factors as well as for several other
easures including serum albumin, bilirubin, creatinine,
nd uric acid. Differences between cases and controls were
imilar to those shown in Table 1 for men and women
onsidered separately and among those using or not using
ipid-lowering medication (data not shown).
The risks of CAD across increasing strata of plasma TGs
re shown in Table 2, excluding subjects with type III
yperlipidemia, who are considered separately. Because
lasma HDL-cholesterol is inversely correlated with plasma
Gs (r  0.35 in cases and 0.40 in control subjects,
oth p  0.0001) and because adjustment for HDL-
holesterol frequently diminishes associated risk of plasma
Gs, models were tested with and without adjustment for
ses
3)
Control Subjects
(n  1,029)
p ValueSD Mean SD
7.6 53.6 8.8 0.0017
47.4 0.0001
4.9 27.9 5.1 0.0103
27.2 0.0001
6.0 0.0001
22.4 0.0001
16.8 0.0048
9.1 0.0001
21.1 121 17.4 0.0001
11.2 72.3 11.0 0.0001
45.9 91.3 19.0 0.0001
0.35 4.30 0.30 0.0001
0.371 0.649 0.345 0.0006
0.523 0.918 0.301 0.0001
1.51 5.59 1.49 0.0001
47 188 34 0.0001
133 155 98 0.0001
12.0 50.2 15.0 0.0001
42 106 28 0.0001
29.9 31.2 20.8 0.0001
0.98 0.0019
s. Differences were tested by chi-square analysis or Student
ry artery disease; HDL  high-density lipoprotein; LDL D Ca
 65
ontrolDL-cholesterol (and other TG-associated risk factors). In
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lso tested with and without similar adjustment for plasma
Gs. Odds ratios for premature familial CAD were similar
or men and women considered separately and are therefore
hown with genders combined. Generally, TG-related risks
ere affected more by adjustment for HDL-cholesterol and
ther risk factors than HDL-associated risk was affected by
djustment for plasma TGs. Nevertheless, plasma TGs 200
g/dl or above and type III hyperlipidemia remained
ignificantly associated with premature familial CAD re-
ardless of adjustment for HDL-cholesterol and other risk
actors. Risk associated with lesser elevations of plasma TGs
ppeared to be more dependent on HDL-cholesterol.
There were 61 control subjects and 114 case subjects
aking beta-blockers at the time of blood draws. Although
Gs were 18.8 mg/dl (p  0.04) higher in control subjects
aking beta-blockers and 40.2 mg/dl higher in cases taking
eta-blockers compared with nonusers in each group, risk
stimates associated with TG categories shown in Table 2
ere not materially affected by excluding those taking
eta-blockers or by including use of beta-blockers as a
ovariate in multiple logistic models.
To further examine possible interactions between plasma
Gs and HDL-cholesterol, combinations of different strata
or each variable were modeled. Results of these analyses are
hown in Table 3 and Figure 1. In this model, the estimated
AD risk associated with type III hyperlipidemia risk was
ven more elevated. Trends in CAD risk are apparent for
ncreasing level of plasma TGs at all levels of HDL-
holesterol. For HDL-cholesterol there was a steep, statis-
able 2. Odds Ratio From Multiple Logistic Regression for Trig
N in Category
(Cases, Control Subjects)
riglyceride categories
100 mg/dl 89, 284
100–149 mg/dl 171, 325
150–199 mg/dl 386, 420
200–299 mg/dl 144, 150
300–499 mg/dl 74, 49
500–799 mg/dl 19, 7
800 mg/dl 2, 1
Type III hyperlipidemia 22, 10
DL-cholesterol categories
25 mg/dl 30, 8
25–29 mg/dl 59, 32
30–34 mg/dl 123, 94
35–39 mg/dl 112, 134
40–49 mg/dl 174, 269
50–59 mg/dl 89, 240
60 mg/dl 37, 242
here were a total of 653 cases and 1,029 control subjects. In this analysis, patient
inimally adjusted models variables included were age, gender, cigarette smoking, an
stimates, HDL was not included in the minimally adjusted model. For the HDL cat
ndependent variables were age, gender, smoking hypertension, diabetes, alcohol use
s a continuous variable for the triglyceride categories or triglycerides as a continuou
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.ically significant gradient of increasing risk associated with
mecreasing levels within all TG strata, even when TGs were
100 mg/dl (data not shown for TGs 100 mg/dl).
We examined whether potential interactions among var-
ous features of the metabolic syndrome affected CAD risk
rediction. Because waist circumference was not available
or the premature familial CAD cases, a cut point of BMI
30 kg/m2 was adopted as a surrogate marker for central
besity. Our definition of metabolic syndrome was other-
ise the same as the Adult Treatment Panel III guidelines
29). In univariate analysis, the metabolic syndrome was
ssociated with an odds ratio for premature familial CAD of
.8 (95% confidence interval [CI] 2.2 to 3.4, p  0.0001),
hich persisted after adjustment for age, gender, cigarette
ide and HDL Categories
nimally Adjusted Model* Fully Adjusted Model*
(95% CI) p Value OR (95% CI) p Value
) — 1.0 () —
1.04–2.1) 0.030 1.2 (0.81–1.8) 0.34
1.2–2.6) 0.0027 1.1 (0.70–1.7) 0.72
1.3–2.7) 0.0011 1.7 (1.1–2.6) 0.012
2.3–6.3) 0.0001 2.8 (1.6–4.9) 0.0003
5.3–41.6) 0.0001 11.4 (3.4–38.0) 0.0001
2.9–332) 0.0051 5.0 (0.29–85.1) 0.27
2.0–13.8) 0.0008 5.4 (1.9–15.4) 0.0016
11.1–75.3) 0.0001 14.8 (4.8–45.4) 0.0001
3.9–13.2) 0.0001 5.1 (2.4–10.9) 0.0001
2.9–7.4) 0.0001 3.4 (1.9–6.4) 0.0001
1.7–4.2) 0.0001 2.0 (1.1–3.6) 0.015
1.4–3.1) 0.0003 1.9 (1.1–3.2) 0.013
0.82–1.9) 0.30 1.4 (0.85–2.5) 0.17
) — 1.0 () —
type III hyperlipidemia were not included in other triglyceride categories. *In the
L-cholesterol besides the categories shown in the table. For the triglyceride category
s, triglycerides were not included in the minimally adjusted model. In the full model,
o), measured LDL-cholesterol, albumin, bilirubin, creatinine and HDL-cholesterol
ble for the HDL categories.
able 3. Odds Ratios for Different Combinations of Plasma
riglycerides and HDL-Cholesterol
Triglycerides HDL Cholesterol OR (95% CI) p Value
ype III hyperlipidemia — 9.7 (3.4–27.6) 0.0001
200 mg/dl 50 mg/dl 1.0 () —
00–299 mg/dl 50 mg/dl 1.1 (0.45–2.8) 0.80
00 mg/dl 50 mg/dl 7.9 (1.1–54.0) 0.036
200 mg/dl 40–49 mg/dl 1.3 (0.86–1.9) 0.22
00–299 mg/dl 40–49 mg/dl 3.7 (2.0–7.0) 0.0001
00 mg/dl 40–49 mg/dl 6.7 (2.4–19.0) 0.0003
200 mg/dl 30–39 mg/dl 2.2 (1.4–3.4) 0.0003
00–299 mg/dl 30–39 mg/dl 3.1 (1.8–5.2) 0.0001
00 mg/dl 30–39 mg/dl 4.3 (2.1–8.6) 0.0001
200 mg/dl 30 mg/dl 5.7 (2.4–13.1) 0.0001
00–299 mg/dl 30 mg/dl 6.1 (2.3–16.5) 0.0003
00 mg/dl 30 mg/dl 17.2 (7.2–41.2) 0.0001
ndependent variables in the model include all those in the fully adjusted model in
able 2. Odds ratios and p values are in reference to persons without type III
yperlipidemia with plasma triglycerides 200 mg/dl and HDL-cholesterol 50lycer
Mi
OR
1.0 (
1.5 (
1.8 (
1.9 (
3.8 (
14.8 (
33.0 (
5.2 (
28.9 (
7.2 (
4.6 (
2.7 (
2.1 (
1.3 (
1.0 (
s with
d LD
egorie
(yes/ng/dl.
Abbreviations as in Tables 1 and 2.
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ogistic model (odds ratio 3.0, 95% CI 2.3 to 3.8, p 
.0001).
The degree of independence of the various components
f the metabolic syndrome in predicting CAD risk remains
nclear. We therefore examined intercorrelations between
Gs and the other components of the metabolic syndrome.
revalence and levels of each factor in both cases and
ontrols increased as plasma TGs rose, as shown in Figure
. Trends for these relationships were all highly significant
mong both case and control groups considered separately
most with p  0.0001) (Fig. 2). Nevertheless, there was no
vidence for interaction between plasma TGs and HDL-
holesterol, hypertension, or LDL cholesterol in predicting
AD risk; the contribution of plasma TGs to CAD risk
emained independent. Although the prevalence of all the
ther features of the metabolic syndrome increased with
ncreasing BMI, BMI was not independently associated
ith CAD risk (data not shown).
Because hypertension has been strongly implicated in the
AD risk associated with dyslipidemia in prior studies, we
lso examined hypertension status with high or low TGs
nd HDL-cholesterol (above and below 200 and 40 mg/dl,
espectively) and found that hypertension added indepen-
ently to CAD risk within each lipid category (Fig. 3).
Patients with premature familial CAD and type III
yperlipidemia were the same age at the time of screening as
ther CAD cases and had similar age at onset of CAD (50.1
7.1 years vs. 47.8 7.0 years, p 0.12); they had similar
MI and gender distributions compared with other CAD
ases. Compared with other CAD cases, type III cases had
igher plasma total cholesterol (287  60 mg/dl vs. 216 
5 mg/dl, p  0.0001), TGs (268  103 mg/dl vs. 203 
33 mg/dl, p  0.025), and, as expected, much higher
easured VLDL-cholesterol (100.0  46.2 mg/dl vs. 38.4
igure 1. Odds ratios for premature coronary artery disease in mutually
onfidence intervals and p values are given in Table 3.26.9 mg/dl, p  0.0001), and by definition a higher ratio Tf measured VLDL-cholesterol/plasma TGs (0.370 
.065 mg/dl vs. 0.188 0.047 mg/dl, p 0.0001). Despite
igher total cholesterol and TGs in type III cases, their
easured LDL- and HDL-cholesterol were not different.
revalence of diabetes, hypertension, and use of lipid-
owering medications and estrogen were also similar in type
II versus other CAD cases.
Because other studies have utilized cut points of plasma
Gs at 200 mg/dl and 800 mg/dl and HDL-cholesterol at
0 mg/dl, we also provide estimates of CAD risk for
ategories based on these cut points considering patients
ith type III hyperlipidemia as a separate category in the
ame model (Fig. 4). Risks in men and women considered
eparately were nearly identical except for TGs800 mg/dl,
or which estimated risk appeared much higher for women
han men (though estimates for both genders had very wide
onfidence intervals and the differences were nonsignificant;
ata not shown).
ISCUSSION
ur principal finding was that plasma TGs predicted CAD
isk independent of total cholesterol and HDL-cholesterol.
he fact that CAD risk was increased substantially with TG
levations beginning at 200 mg/dl is of clinical significance
ecause this is a common and relatively mild lipid abnor-
ality. This is of even greater importance because the
ncrease in CAD was seen even with HDL-cholesterol
bove 40 mg/dl. Furthermore, this risk was independent of
ther features of the metabolic syndrome. Risk of CAD was
pproximately doubled with either TGs 200 mg/dl or
DL-cholesterol 40 mg/dl. The presence of both was
ssociated with a four-fold increase in risk (Fig. 4).
Only one other published study has found such a strong
nd independent relationship between TGs and CAD.
sive plasma triglyceride and high-density lipoprotein (HDL) categories.otal cholesterol, TGs, and HDL were each independent
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egression model in United Kingdom men (30). In contrast,
ost other studies have failed to see such a strong indepen-
ent association. For example, CAD risk increased with
ncreasing TG in the Physician’s Health Study and was
ndependent of HDL-cholesterol, but was not independent
f serum total cholesterol (31). More commonly, plasma
Gs were reported to be a risk factor only when HDL-
holesterol was low (13,14). Others have reported interac-
ions of the relationship between CAD and plasma TGs
ith total cholesterol as well as age (32,33). It is possible
hat the studies that found increased risk with high TGs
nly when HDL was low had insufficient power to detect an
ndependent contribution of elevated TGs with higher
DL-cholesterol. This is because patients with both high
Gs and high HDL-cholesterol are a relatively uncommon
ubgroup.
We found remarkably increased CAD risk for persons
igure 2. Prevalence of metabolic syndrome and contributing factors by pla
hows triglyceride strata (mg/dl). Cut points for factors of the metabolic syn
tudy was defined as BMI 30 kg/m2. All trends were significant with p 
or trend was 0.002. Patients with type III hyperlipidemia were excluded.ith plasma TGs in the 500 to 799 mg/dl range and we wound that this high risk persisted even with adjustment for
DL and other risk factors (odds ratio  11.4, 95% CI 3.4
o 38.0). Although the confidence interval was relatively
ide, the finding was highly significant (p  0.0001) and
ssentially unaffected by eliminating users of beta-blockers
r adjusting for use of beta-blockers in the multiple logistic
odels. This degree of excess risk might seem greater than
he apparently modest risk associated with higher TGs in
he meta-analyses of Hokanson and Austin (1,34). These
nvestigators noted statistically significant relative risks of
.32 and 1.76 for each 1 mmol/l (88.6 mg/dl) increase in
Gs among men and women, respectively. Risks were
iminished but remained significant with adjustment for
DL. Assuming a 50% increase in risk for each 1 mmol/l
ise in TGs (approximate average from the above cited
eta-analyses) (1,34) and given a 5 mmol/l increase from
ur lowest category to the 500 to 799 mg/dl range, one can
alculate an expected relative risk of 7.6, which is well
riglyceride concentration in cases (A) and control subjects (B). The legend
e are as defined by ATP-III except body mass index (BMI) which for this
01 except for the high blood pressure (BP) in cases for which the p value
 high-density lipoprotein.sma t
dromithin the confidence interval we found for this category.
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Gs in this range to have much statistical power to examine
isk associated with TGs above 500 mg/dl.
Type III hyperlipidemia (also called familial dysbetali-
oproteinemia) is defined by the accumulation in plasma of
ighly atherogenic, abnormal, cholesterol-enriched rem-
ants of TG-rich lipoproteins (35). Although a high prev-
lence of premature atherosclerosis in coronary and other
rteries is readily apparent from case series of patients with
ype III hyperlipidemia (18,36–42), no quantitative esti-
ates of risk have previously been available. Our study is
pparently the first to perform ultracentrifugation in all
ases and controls and thereby identify type III hyperlipid-
mia by classic methods even in patients with mild hyper-
riglyceridemia. Surprisingly, 65.6% and 87.5% of patients
e identified as having type III disease would not have been
dentified if we had restricted ultracentrifugation only to
hose with TGs 300 mg/dl or 400 mg/dl, respectively.
Our population-based calculations of risk of premature
amilial CAD associated with type III hyperlipidemia (odds
atio from 5 to 10 depending on the model) are consistent
ith rough estimates of risk based on the prevalence of type
II in the general population and among premature CAD
ases. In the Lipid Research Clinics Prevalence Study, type
II hyperlipidemia was found in 0.4% of men in the general
opulation (43). The somewhat higher prevalence of type
II in our controls (10 of 1,019, or 0.97%) may possibly be
ue to the increase in the prevalence of obesity since the
ime when the Lipid Research Clinics study was performed,
8 years before our study. In the series of premature CAD
ases identified by Goldstein et al. (44), type III was
eported in 2.5% to 5% of 156 premature CAD cases with
yperlipidemia for whom ultracentrifugation was per-
igure 3. Odds ratios of premature coronary artery disease in triglyceride (T
or normal blood pressure (NBP), high HDL, high TG and low HDL, low
re significant at p 0.0001. HBP  high blood pressure.ormed, similar to the prevalence in our cases (22 of 653, or t.4%). Plasma lipid levels in type III hyperlipidemia can be
ighly variable, but levels found in our type III patients were
imilar to those reported by Goldstein et al. (44) in their
ype III patients with CAD.
Several measures of increased remnant accumulation are
ssociated with elevated CAD risk. Unfortunately, estimates
f the degree of risk elevation vary substantially, depending
pparently on the method or parameter used (45–48). In
ontrast, little or no excess CAD risk has been reported by
ome investigators for those with hyperchylomicronemia or
ype V hyperlipidemia even though TG levels are much
igher (15,16). The variability of risk with hypertriglyceri-
emia probably is related to the particular species of
G-rich particles present in excess. For example, in diabetic
holesterol-fed rabbits, particles 75 nm in diameter (in-
luding larger VLDL and chylomicrons) infiltrated the
rtery wall poorly if at all and therefore presumably made
ittle direct contribution to atherogenesis (49). Unlike
DL-cholesterol, therefore, risk associated with total
lasma TGs may not be appropriately modeled by a simple,
onotonically increasing risk function. Rather, CAD risk
rom hypertriglyceridemia may be more accurately esti-
ated by examination of specific TG-related disorders.
The CAD risks we found for other standard risk factors
n this study are comparable to prior reports and generally
upport a multifactorial approach to CAD prevention (29).
ur findings also corroborate findings regarding serum
lbumin (50,51) (inversely correlated with high sensitivity
-reactive protein) (52) and bilirubin (53–56).
There are several limitations to our study. As this is a
ase-control study, we cannot report on absolute risk asso-
iated with the various lipid levels nor can we demonstrate
emporal sequence (i.e., that risk factors were present before
gh-density lipoprotein (HDL) categories and by hypertension. Odds ratios
categories were significant at p  0.006 and 0.0010 respectively. All othersG)/hihe onset of CAD). There are, however, data from prospec-
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o two months post-infarct) in untreated lipids after the
linical diagnosis of CAD (57–59). A related limitation is
he effect of differential intervention on lipids because, as
xpected, our CAD cases had more aggressive treatment
han our control cases. Greater lipid intervention among
AD patients would result in lower LDL-cholesterol and
G levels and a resulting underestimation of the odds ratio
ssociated with these lipids. Lipid interventions also tend to
ave a salutary, though generally smaller, effect on HDL-
holesterol. Therefore, estimates of risk reported in our
tudy are likely to be conservative. Importantly, however,
estricting analyses to those not taking lipid-lowering med-
cation or inclusion of such therapy as an effect variable did
ot materially affect our results (data not shown). This may
e due, in part, to the relative infrequency of lipid-lowering
rug therapy in our premature familial CAD cases, reflect-
ng usual clinical practices in the mid-1990s as reported in
everal surveys (60,61). Further, there were no significant
ifferences in lipid levels among our cases comparing those
aking with those not taking lipid-lowering medication
data not shown), possibly reflecting relatively ineffectual or
nadequate treatment primarily restricted to patients with
igh untreated levels.
Hypertension was considerably more frequent among our
ases than control subjects. We cannot exclude the possi-
ility that some of the higher TGs and lower HDL-
holesterol seen in our cases may have been due to greater
se of diuretics and beta-blockers. Recent studies of these
gents suggest, however, that the long-term lipid effects of
hese agents are small, especially at the lower doses used
redominately during the past 10 to 15 years (62–66).
igure 4. Summary of coronary artery disease risk (odds ratios and 95%
stimated simultaneously in a multiple logistic regression model adjusting f
ow-density lipoprotein cholesterol. HDL  high-density lipoprotein; TGurthermore, inclusion of hypertension as a term in the tultiple logistic regression model would help mitigate any
onfounding due to antihypertensive medications.
Potential limitations of case-control studies in general
nclude recall bias and selection bias. Because all cases and
ontrols were examined in our clinic with blood testing
erformed by a single laboratory, various forms of informa-
ion bias were minimized. In particular, recall bias, a
ommon problem in case-control studies as opposed to
rospective studies, was minimized in this study because all
ubjects were interviewed in our clinic and cases were not
sked to recall factors present before the onset of their CAD
ther than lifetime use of cigarettes. Inappropriate selection
f cases and controls can inadvertently introduce bias into a
ase-control study. Sampled cases should be representative
f all cases arising from a given population and controls
hould be representative of the general population. Our
AD cases were defined as premature and familial, thus
otentially limiting generalization of our findings to non-
amilial or older onset CAD. Nevertheless, a large propor-
ion of premature CAD cases do show evidence for a
ositive family history of CAD (67). As our premature
amilial CAD cases are the result of an intensive search for
uch cases among the major urban and suburban areas of
tah, we believe these to be representative of all such cases
n Utah. As participants in the multicenter Family Heart
tudy (25) (with recruitment sites at Framingham, Minne-
polis, Utah, and Forsyth County, North Carolina), we
ere able to directly compare our premature familial CAD
ases and controls with premature CAD cases and general
opulation controls in the Family Heart Study (19). The
efinitions of premature CAD in the Family Heart Study
ere identical to our current study, though not all cases in
dence intervals) associated with commonly used cut points. Risks were
, gender, hypertension, diabetes, serum albumin, bilirubin, creatinine, and
riglycerides.confihe Family Heart Study had positive family histories of
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eart Study, our cases were about five years younger with a
lightly higher percentage of men, higher blood pressure,
nd substantially lower alcohol use. Other risk factors and
ipids in our CAD cases were similar to CAD patients at
ther sites in the Family Heart Study, particularly after
ontrolling for alcohol use (data not shown). Only living
AD patients could have participated in our study. As
urvivors of clinically apparent CAD could represent less
everely affected patients as compared with those who had
ied, bias may be introduced that would diminish odds
atios (as more severe CAD would be expected to have more
evere risk factors). This limitation is common to all
ase-control studies of CAD.
The selection of an appropriate control group is also
ritical to the validity of a case-control study. One of our
ontrol groups was randomly selected from a general pop-
lation (Health Family Tree Program), which on close
valuation represented largely suburban families with very
ow use of alcohol and prevalence of ever smoking. The
econd control group, though not randomly selected, rep-
esented primarily urban couples. Comparison of these
ontrol groups with control groups from the Family Heart
tudy (19) again showed much lower smoking rates and
lcohol use in the controls from the Health Family Tree
rogram with more intermediate levels in the urban couples.
ther risk factors were comparable with controls at other
amily Heart Study sites. Combining the control groups
herefore provides a wider representation of the general
tah population (both urban and suburban). The very
imilar estimates of risk using each of these control groups
n separate analyses further justifies combining the two
ontrol groups and provides strong evidence for the validity
f our findings.
In conclusion, we found a strongly increased risk for
remature familial CAD with elevated plasma TGs. Impor-
antly, this excess risk begins at a mild and relatively
ommon TG elevation of just 200 mg/dl, and is indepen-
ent of plasma HDL-cholesterol, other elements of the
etabolic syndrome, and other CAD risk factors. In addi-
ion, for the first time we provide a quantitative, population-
ased estimate of the markedly elevated risk of CAD
ssociated with type III hyperlipidemia determined by
ltracentrifugation.
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